CXCR4 and lymphoma: Beyond an improved read-out relative to the reference radiotracer [18F]FDG, however, [68Ga]Ga-PentixaFor also allows for quantification of CXCR4 expression in lymphoma manifestations in vivo, thereby identifying patients that could therefore be eligible for CXCR4-directed radioligand therapy (RLT) using the theranostic, β-emitting twin [177Lu]Lu- or [90Y]Y-PentixaTher12.